Liminal BioSciences Outlines Plans To Further Develop Its Lead Compound
Liminal BioSciences Inc (NASDAQ:LMNL) has provided an update on plans for further developing its lead compound fezagepras. The announcement follows the completion of analysis of the pharmacokinetic (PK) data from its Phase 1 MAD study of fezagepras in healthy volunteers. There were no significant drug-related safety findings in the study. "...the PK data…
Benzinga ·
Benzinga
